Plasma Aβ42/Aβ40 and p-tau181 Predict Long-Term Clinical Progression in a Cohort with Amnestic Mild Cognitive Impairment
Zhenxu Xiao(Fudan University), Qianhua Zhao(Fudan University), Wanqing Wu(East China University of Science and Technology), Xiaoxi Ma(Fudan University), Ding Ding(Fudan University), Li Zheng(Fudan University), Jianfeng Luo(Chinese Academy of Medical Sciences & Peking Union Medical College), Keliang Chen(Fudan University), Xiaoniu Liang(Fudan University), Jiaying Lu(Ministry of Education of the People's Republic of China), Saineng Ding(Fudan University), Qiqi Lei(South China Agricultural University)
Cited by 32
Related Papers
RETRACTED: 6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2021|4.3k
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study
|The Lancet|2023|892
A 36-week multicenter, randomized, double-blind, placebo-controlled, parallel-group, phase 3 clinical trial of sodium oligomannate for mild-to-moderate Alzheimer’s dementia
|Alzheimer s Research & Therapy|2021|200
Environmental occurrence, toxicity concerns, and biodegradation of neonicotinoid insecticides
|Environmental Research|2022|169
Bioremediation potential of laccase for catalysis of glyphosate, isoproturon, lignin, and parathion: Molecular docking, dynamics, and simulation
|Journal of Hazardous Materials|2022|128